Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.
BSXNegative Net Change ECLPositive Net Change ALGNNegative Net Change MCKNegative Net Change
earnings medical medical-devices
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
UTHRNegative Net Change LGNDPositive Net Change ANIPNegative Net Change ESPRNegative Net Change
earnings medical
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
LGNDPositive Net Change AGENNegative Net Change VKTXPositive Net Change TVTXPositive Net Change
biotechs earnings medical
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
RMDNegative Net Change BIONegative Net Change MEDPNegative Net Change EHCNegative Net Change
earnings medical medical-devices
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
by Zacks Equity Research
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.
RMDNegative Net Change MYGNPositive Net Change MEDPNegative Net Change EHCNegative Net Change
earnings medical medical-devices
Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.
BSXNegative Net Change ECLPositive Net Change ALGNNegative Net Change NVRONegative Net Change
earnings medical medical-devices
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
LGNDPositive Net Change ANIPNegative Net Change ITCINegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
LGNDPositive Net Change PCRXPositive Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.
BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change INSPNegative Net Change
earnings medical medical-devices
Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up
by Zacks Equity Research
Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.
BSXNegative Net Change ECLPositive Net Change ALGNNegative Net Change MASINegative Net Change
earnings medical medical-devices
Pediatrix (MD) Q1 Earnings Beat on Hospital Contract Fees
by Zacks Equity Research
Pediatrix's (MD) Q1 results benefit from higher same-unit revenues, resulting from growing patient volumes, partly offset by high costs. It continues to expect 2024 adjusted EBITDA within $200-$220 million.
MOHNegative Net Change MDNegative Net Change CNCNegative Net Change ENSGNegative Net Change
earnings medical
Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
BSXNegative Net Change ECLPositive Net Change ALGNNegative Net Change FMSPositive Net Change
earnings medical medical-devices
Why Earnings Season Could Be Great for Viatris (VTRS)
by Zacks Equity Research
Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
VTRSPositive Net Change
medical
3 GARP Stocks to Scoop up for Maximum Returns
by Zacks Equity Research
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH and KTB are some stocks that hold promise.
RMDNegative Net Change BAHNegative Net Change KTBNegative Net Change
business-services consumer-discretionary medical
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
ARGXNegative Net Change
biotechnology medical
Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
RMDNegative Net Change PENNegative Net Change MEDPNegative Net Change EHCNegative Net Change
earnings medical
4 Stocks to Buy in a Thriving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
DVANegative Net Change EHCNegative Net Change PNTGPositive Net Change OPCHNegative Net Change
medical medical-devices
Why Earnings Season Could Be Great for Nuvalent (NUVL)
by Zacks Equity Research
Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NUVLNegative Net Change
earnings medical
Should You Buy Insmed (INSM) Ahead of Earnings?
by Zacks Equity Research
Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
INSMNegative Net Change
earnings medical
5 Growth Stocks to Buy for Steady Returns in May
by Nalak Das
We have narrowed our search to five growth stocks that have solid upside left for 2024. These stocks are NFLX, WING, PATH, SKX and MEDP.
NFLXPositive Net Change SKXPositive Net Change PATHNegative Net Change WINGNegative Net Change MEDPNegative Net Change
business-services consumer-discretionary medical restaurants
Best Momentum Stock to Buy for May 8th
by Zacks Equity Research
HIMS, CHRW and WRK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 8, 2024.
CHRWPositive Net Change WRKPositive Net Change HIMSNegative Net Change
medical transportation
3 Stocks Backed by High Efficiency to Strengthen Your Portfolio
by Santanu Roy
Invest in companies like Option Care Health (OPCH), ReWalk Robotics Ltd. (LFWD) and Garmin (GRMN), as they boast higher efficiency levels.
GRMNNo Net Change OPCHNegative Net Change LFWDPositive Net Change
communications medical medical-devices
Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow
by Zacks Equity Research
Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.
RDYPositive Net Change LGNDPositive Net Change ANIPNegative Net Change BBIONegative Net Change
earnings medical pharmaceuticals
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
by Zacks Equity Research
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.
RMDNegative Net Change VCYTNegative Net Change MEDPNegative Net Change EHCNegative Net Change
earnings medical medical-devices
Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.
RMDNegative Net Change GMEDPositive Net Change MEDPNegative Net Change EHCNegative Net Change
earnings medical medical-devices